People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Shares of RH fell sharply after hours on Wednesday after the luxury furniture chain's full-year sales outlook came in shy of expectations, amid a forecast of what it characterized as a "higher-risk ...

Ford’s first quarter sales were off 1.3% compared to a year earlier, largely due to the discontinuation last year of its Ford ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned it was considering legal action against companies it believes to be ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

As it stands today, Mounjaro is Lilly's largest source of revenue while Zepbound is ... from the initial forecast of 56.5 billion yen. The company cited delays in the sales launch in the U.S ...

Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes ... hit Wall Street's lofty forecasts.

Zepbound is Eli Lilly's biggest growth driver at the moment, but it isn't the only drug pushing total sales higher for this well-established pharmaceutical giant. Its fourth-quarter revenue not ...